Article

Gregory J. Riely on the Identification and Treatment of MET Exon 14 Skipping Mutations

Author(s):

Gregory J. Riely

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses identifying and treating patients with MET exon 14 skipping mutations in lung cancer.

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses identifying and treating patients with MET exon 14 skipping mutations in lung cancer.

Related Videos
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with brown and grey hair.
Image of man with grey hair.
Image of bald man in suit.
Related Content
Illustration of lungs.
January 11th 2025

FDA Grants Fast Track Designation for Abenacianine in Lung Cancer Surgery

Spencer Feldman
The FDA has granted fast track designation for abenacianine to help surgeons better visualize lung tumors during minimally invasive surgery.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lung cancer.
January 8th 2025

Rybrevant Plus Lazcluze Improves Survival for EGFR+ NSCLC

Alex Biese
First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or metastatic NSCLC.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
FDA grants priority review to an NDA for taletrectinib in ROS1+ NSCLC.
January 4th 2025

FDA Accepts New Drug Application For Taletrectinib in ROS1+ NSCLC

Ryan Scott
The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell lung cancer.
Here is the latest cancer news.
January 3rd 2025

Greg Gumbel Died of Cancer, Olympian Gabriela Dabrowski Competed During Treatment and More

Alex Biese
From tennis star Gabriela Dabrowski sharing details of her breast cancer journey to Greg Gumbel and Linda Lavin dying, here is the latest cancer news.